RARE DISEASES

Strategic Advisory Group

ABOUT

Rare Diseases

Strategic Advisory Group

The council of the European Union states “Rare Diseases are a threat to the health of EU citizens in so far as they are life threatening or chronically debilitating diseases with a low prevalence and a high level of complexity”. In 2009 the European Rare Diseases Patients Organisation (EURORDIS) published the “Voice of 12,000 patients”. Individuals with a rare disease and their families reported on years of waiting for a diagnosis, after misdiagnosis and numerous physicians’ visits. Some were rejected by health care professionals because of the complexity or associated symptoms.

EAP responded with the establishment of a Rare Diseases Strategic Advisory Group. The majority of the over 6,000 different rare diseases present in childhood. In the paper “The Importance of Rare Diseases: from the gene to society”, Dodge et al ADC, 2010, is described why and which support is needed from European paediatricians for the thousands of children with rare, disabling and life-threatening conditions.

Rare Diseases Strategic Advisory Group members have been organising and presenting in over 10 different national and international paediatric and rare disease conferences.

Appropriate early identification, diagnostic confirmation, and longitudinal management provide the gateway to the prevention of illness and optimal overall health for children with rare and chronic conditions. The Rare Diseases Working Group supports actions towards a joint global reinforcement of a holistic approach of each child with a rare and chronic condition.

Agendas

 

PUBLISHED ARTICLES

Universal Health Coverage “Leave No Child Behind”

Methodology for production of best practice guidelines for rare diseases, 2014

RARE-Bestpractices: a platform for sharing best practices for the management of rare diseases, 2014

The Importance of Rare Diseases: from the Gene to Society, 2011

Your Enquiries Are Welcome

We will respond to you by Email

Core-MD Project

Coordinating Research and Evidence for Medical Devices (CORE-MD)

New ways to test high-risk medical devices.

 

Manufacturers of medical devices need to test their products before being allowed to market them. Specifically, they require clinical data showing their medical device is safe and efficient. In this context, the EU-funded CORE-MD project will translate expert scientific and clinical evidence on study designs for evaluating high-risk medical devices into advice for EU regulators. The project will propose how new trial designs can contribute and suggest ways to aggregate real-world data from medical device registries.


It will also conduct multidisciplinary workshops to propose a hierarchy of levels of evidence from clinical investigations, as well as educational and training objectives for all stakeholders, to build expertise in regulatory science in Europe. CORE–MD will translate expert scientific and clinical evidence on study designs for evaluating high-risk medical devices into advice for EU regulators, to achieve an appropriate balance between innovation, safety, and effectiveness. A unique collaboration between medical associations, regulatory agencies, notified bodies, academic institutions, patients’ groups, and health technology assessment agencies, will systematically review methodologies for the clinical investigation of high-risk medical devices, recommend how new trial designs can contribute, and advise on methods for aggregating real-world data from medical device registries with experience from clinical practice The consortium is led by the European Society of Cardiology and the European Federation of National Associations of Orthopaedics and Traumatology, and involves all 33 specialist medical associations that are members of the Biomedical Alliance in Europe.

EAP Representative: